With an Unrestricted Grant from Boehringer-Ingelheim by Marcus Altfeld, Boston (USA) Georg Behrens, Hannover Patrick Braun, Aachen U

Total Page:16

File Type:pdf, Size:1020Kb

With an Unrestricted Grant from Boehringer-Ingelheim by Marcus Altfeld, Boston (USA) Georg Behrens, Hannover Patrick Braun, Aachen U With an unrestricted grant from Boehringer-Ingelheim By Marcus Altfeld, Boston (USA) Georg Behrens, Hannover Patrick Braun, Aachen U. Fritz Bredeek, San Francisco (USA) Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Andrea Gori, Milan (Italy) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Peter Krings, Essen Christoph Lange, Borstel Thore Lorenzen, Hamburg Christoph Mayr, Berlin Giovanni Battista Migliori, Tradate (Italy) Till Neumann, Essen Tim Niehues, Krefeld Christian Noah, Hamburg Falk Ochsendorf, Frankfurt Ramona Pauli, Munich Mario Ostrowski, Toronto (Canada) Ansgar Rieke, Koblenz Jürgen Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Andrea Rubbert-Roth, Cologne Bernhard Schaaf, Dortmund Christiane Schieferstein-Knauer, Frankfurt Reinhold E. Schmidt, Hannover Helmut Schöfer, Frankfurt Ulrike Sonnenberg-Schwan, Munich Matthias Stoll, Hannover Hendrick Streeck, Boston (USA) Jan Thoden, Freiburg Nils Venhoff, Freiburg Mechthild Vocks-Hauck, Berlin Ulrich A. Walker, Basel (Switzerland) Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2012/2013 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Editors Christian Hoffmann, M.D., Ph.D. ICH Mitte (Infektionsmedizinisches Centrum Hamburg) Dammtorstrasse 27 20354 Hamburg, Germany Phone: + 49 40 63607963 Fax: + 49 40 63607964 email: [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 email: [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2012/13 have made every effort to provide information that is accurate and complete as of the date of publication. However, in view of the rapid changes occurring in HIV medical science, HIV prevention and policy, as well as the possibility of human error, this site may contain technical inaccuracies, typographical or other errors. Readers are advised to check the product information currently provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administration, and contraindications. It is the responsibility of the treating physician who relies on experience and knowledge about the patient to determine dosages and the best treatment for the patient. The information c ontained herein is provided "as is" and without warranty of any kind. The contributors to this site, including the editors and the Medizin Fokus Verlag, disclaim responsibility for any errors or omissions or for results obtained from the use of information contained herein. © 2012 by Medizin Fokus Verlag, Hamburg Layout and Printing: Schröders Agentur, Vopeliuspfad 6, 14169 Berlin Pictogram: Tobias Emskoetter, Hamburg ISBN: 978-3-941727-11-3 V Preface 2012/2013 The goal remains the same – to make a textbook that is easily readable and can be used in the daily practice of HIV treatment. As in previous years, all the chapters of HIV 2012/2013 have been thoroughly revised. Again, special emphasis was put on actuality. This is underlined by the fact that in the antiretroviral therapy chapter alone, more than 200 are dated in the years 2011 and 2012. Previous issues of the progenitor “HIV Medicine” were available in several languages, such as Spanish, Romanian, Portuguese, Vietnamese and Persian. There have been a Russian issue in 2011. Under certain conditions, the editors and the authors of this book may agree to remove the copyright on HIV 2012/2013 for all languages except English and German. You could therefore translate the content of this book into any language and publish it under your own name, without paying a license fee. HIV 2012/2013 is also freely available on the Internet (www.hivbook.com), because we firmly believe that this is the way medical textbooks should be handled in the 21st century. Research, knowledge, and expertise in the field of HIV can be shared and accessible to those who are dedicated to the treatment and care of individuals affected by HIV. Christian Hoffmann, Jürgen K. Rockstroh Hamburg, Bonn – September 2012 Acknowledgments We would like to thank all the authors and all the people who helped us generously to realise this project, especially Laura Belkien, Nicole Bentrup, Daniel D. Breitenstein, Rob Camp, Christian Dedek, Fiona Diekhoff, Beate Doebrich, Sabine Dransfeld, Tobias Emskoetter, Thomas Fischer, André Gaidies, Fiona Gordon-Pietz, Georg Haerter, Iren Güler, Johannes Jongen, Rainer A. Jordan, Brigitte Jung, Anja Keimes, Claudia Kröger, Giao Le, Laura- Sophie Nielsen, Daniela Otto, Britta Ranneberg, Marlene Rodrigues Pereira, Sven Schellberg, Gerald Schröder, Armin Schuster, Maxie Sinner, Victor Stanislevskiy, Hans-Jürgen Stellbrink, and Martin Vogel VI Assistant Editors Rob Camp (Barcelona, Spain) Fiona Diekhoff (Hamburg, Germany) Contributors Marcus Altfeld, MD, PhD Rob Camp Partners AIDS Research Center Phone: +34 93 218 6400 Massachusetts General Hospital [email protected] Bldg. 149, 13th Street, 5th floor Christian Eggers, MD, PhD Charlestown, MA 02129 Abteilung für Neurologie USA Krankenhaus der Barmherzigen Brüder, Phone: +1 617 724 2461 Seilerstätte 2 Fax: +1 617 724 8586 A-4021 Linz [email protected] Phone: +43 732 7897 25305 [email protected] Georg Behrens, MD, PhD Klinische Immunologie Stefan Esser, MD Zentrum Innere Medizin der Department of Dermatology Medizinischen Hochschule University of Essen Carl-Neuberg-Straße 1 Hufelandstrasse 55 D-30625 Hannover D-45122 Essen Phone: +49 511 532 5393 Phone: +49 201-723-3878 Fax: +49 511 532 9067 [email protected] Gerd Fätkenheuer, MD, PhD Patrick Braun Department of Internal Medicine PZB Aachen University of Cologne Blondelstrasse 9 Joseph-Stelzmann-Str. 9 D-52062 Aachen D-50924 Köln Phone: +49 241 470970 [email protected] Fax: +49 241-408652 [email protected] Carole Gilling-Smith, MA, FRCOG, PhD Assisted Conception Unit U. Fritz Bredeek, MD, PhD Chelsea & Westminster Hospital Metropolis Medical PC 369 Fulham Road 2351 Clay Street, Suite 512 GB-London SW10 9NH San Francisco, CA 94115 Phone: +41 20 8746 8922 Phone: +1 415 292-5477 [email protected] Fax: +1 415 292-5490 Andrea Gori, MD Division of Infectious Diseases Thomas Buhk, MD San Gerado Hospital ICH Grindel University Milan-Bicocca Grindelallee 35 Via Pergolesi 33 D-20146 Hamburg IT-20052-Monza Phone: +49 40 41 32 420 Phone: +39 039 233 9310 [email protected] [email protected] Contributors VII Thomas Harrer, MD, PhD Thore Lorenzen, MD Department of Internal Medicine III ifi Institute IUniversitätsklinikum Erlangen Lohmühlenstrasse 5 Krankenhausstraße 12 D-20099 Hamburg D-91054 Erlangen Phone: +49 40 181885 3780 Phone: 49 9131 854 3004 Fax: +49 40 181885 3788 Fax: 49 9131 853 4749 [email protected] [email protected] Christoph Mayr, MD Christian Herzmann, MD MVZ Ärzteforum Seestrasse Clinical Infectious Diseases, Seestrasse 64 Medical Clinic, Research Center Borstel D-13347 Berlin Parkallee 35 Phone: +49 30 455095 0 D-23845 Borstel Fax: +49 30 455095 25 Phone: +49 4537 188 0 [email protected] Giovanni Battista Migliori, MD WHO Collaborating Center for TB and Heinz-August Horst, MD, PhD Lung Diseases University of Kiel, UKSH Fondazione S. Maugeri II. Medical Department Care and Research Institute Chemnitzstraße 33 Via Roncaccio 16 D-24116 Kiel IT-21049 Tradate Phone: +49 431-1697-1207 Phone: +39 0331 829404 Fax: +39 0331 829404 [email protected] Martin Hower Medizinische Klinik Nord Till Neumann, MD Klinikum Dortmund GmbH Universitätsklinikum Essen Hövelstrasse 8 (Gebäude Gesundheitsamt) Klinik für Kardiologie D-44137 Dortmund Hufelandstr. 55 Phone: +49 231-95320 700 D-45122 Essen Fax: +49 231-95320 702 Phone: +49 201 723 4878 [email protected] Fax: +49 201 723 5401 [email protected] Peter Krings, MD Department of Cardiology Tim Niehues, MD, PhD University of Essen Immunodeficiency and Pediatric Hufelandstr. 55 Rheumatology Centre D-45122 Essen Helios Klinikum Krefeld Phone: 49 201-723 85679 Lutherplatz 40 Fax: 49 201-723 5401 D-47805 Krefeld [email protected] Phone: +49 2151 32 2301 Fax: +49 2151 32 2334 Christoph Lange, MD, PhD [email protected] Clinical Infectious Diseases, Medical Clinic, Research Center Borstel Christian Noah, MD Parkallee 35 Labor Lademannbogen D-23845 Borstel Lademannbogen 61-63 Phone: +49 4537 188 332 D-22339 Hamburg Fax: +49 4537 188 313 Phone: +49 40 53805-706 [email protected] [email protected] VIII Contributors Falk Ochsendorf, MD, PhD Bernhard Schaaf, MD, PhD Zentrum der Dermatologie und Klinikum Dortmund GmbH Venerologie Münsterstrasse 240 Klinikum der J.W. Goethe-Universität D-44145 Dortmund Theodor-Stern-Kai 7 Phone: +49 231 95318 100 D-60590 Frankfurt am Main Fax: +49 231 95318 199 Phone: +49 69 6301 6819 [email protected] [email protected] Christiane Schieferstein-Knauer, MD Mario Ostrowski, MD Klinik für Onkologie und Hämatologie Clinical Sciences Division Medizinische Klinik II am Krankenhaus University of Toronto Nordwest GmbH Medical Sciences Building, Rm 6271 Steinbacher Hohl 2-26 1 King's College Circle D-60488 Frankfurt Toronto, ON M5S 1A8 [email protected] Canada Phone: +1 416 946 5805 Reinhold E. Schmidt, MD,
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0306098 A1 Mutz Et Al
    US 200803 06098A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0306098 A1 Mutz et al. (43) Pub. Date: Dec. 11, 2008 (54) PHARMACOKINETICS OF PROTEASE Publication Classification INHIBITORS AND OTHER DRUGS (51) Int. Cl. A 6LX 3L/505 (2006.01) (76) Inventors: Mitchell W. Mutz, La Jolla, CA A63L/4353 (2006.01) (US); Jason E. Gestwicki, Ann C07D 49/12 (2006.01) Arbor, MI (US) C07D 239/04 (2006.01) A6IP3 L/18 (2006.01) Correspondence Address: (52) U.S. Cl. ............ 514/274: 514/291; 546/90; 54.4/316 MINTZ, LEVIN, COHN, FERRIS, GLOVSKY (57) ABSTRACT AND POPEO, PC 5 Palo Alto Square - 6th Floor,3000 El Camino Real A method for modulating at least one pharmacokinetic prop PALO ALTO, CA 94306-2155 (US) erty of a protease inhibitor upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 daltons (21) Appl. No.: 12/151,329 comprising the protease inhibitor or an active derivative thereof and a pharmacokinetic modulating moiety. The phar (22) Filed: May 5, 2008 macokinetic modulating moiety binds to at least one intrac ellular protein. The bifunctional compound has at least one (30) Foreign Application Priority Data modulated pharmacokinetic property upon administration to the hostas compared to a free drug control that comprises the Nov. 6, 2006 (US) ................. PCT/US2006/043400 protease inhibitor. FKBP-binding FKBP-binding interface interface Conjugate Target Binding Calcineurin-binding interface Patent Application Publication Dec. 11, 2008 Sheet 1 of 11 US 2008/0306.098 A1 O) \iO Ol cy A- S' O I N CD (5.
    [Show full text]
  • Download Article PDF/Slides
    New Antiretrovirals in Development: Reprinted from The PRN Notebook,™ june 2002. Dr. James F. Braun, Editor-in-Chief. Tim Horn, Executive Editor. Published in New York City by the Physicians’ Research Network, Inc.,® John Graham Brown, Executive Director. For further information and other articles The View in 2002 available online, visit http://www.PRN.org All rights reserved. © june 2002. Roy “Trip” Gulick, md, mph Associate Professor of Medicine, Weill Medical College of Cornell University Director, Cornell Clinical Trials Unit, New York, New York Summary by Tim Horn Edited by Scott Hammer, md espite the fact that 16 antiretro- tiviral activity of emtricitabine was estab- Preliminary results from two random- virals are approved for use in the lished, with total daily doses of 200 mg or ized studies—FTC-302 and FTC-303—were United States, there is an indis- more producing the greatest median viral reported by Dr. Charles van der Horst and putable need for new anti-hiv com- load suppression: 1.72-1.92 log. Based on his colleagues at the 8th croi, held in Feb- pounds that have potent and these data, a once-daily dose of 200 mg ruary 2001 in Chicago (van der Horst, durable efficacy profiles, unique re- was selected for further long-term clinical 2001). FTC-302 was a blinded comparison sistance patterns, patient-friendly dosing study. “This is what we’re looking forward of emtricitabine and lamivudine, both in schedules, and minimal toxicities. To pro- to with emtricitabine,” commented Dr. combination with stavudine (Zerit) and vide prn with a glimpse of drugs current- Gulick.
    [Show full text]
  • ( 12 ) United States Patent
    US010385067B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 385, 067 B2 Carra et al. (45 ) Date of Patent: Aug. 20 , 2019 (54 ) SODIUM (2R , 55 , 13AR ) - 7 , 9 -DIOX0 - 10 ( 56 ) References Cited ( 2 , 4 ,6 - TRIFLUOROBENZYL )CARBAMOYL ) 2 , 3 , 4 , 5 , 7 , 9 , 13 , 13A -OCTAHYDRO - 2 , 5 U . S . PATENT DOCUMENTS METHANOPYRIDO [ 1 ' , 2 ' : 4 , 5 ]PYRAZINO 5 , 814 ,639 A 9 / 1998 Liotta et al . [ 2 , 1 - B ] [ 1 , 3 ]OXAZEPIN - 8 - OLATE 5 , 914 , 331 A 6 / 1999 Liotta et al . 5 ,922 ,695 A 7 / 1999 Arimilli et al . 5 , 935 , 946 A 8 / 1999 Munger, Jr . et al. (71 ) Applicant: Gilead Sciences , Inc ., Foster Ctiy , CA 5 , 977 , 089 A 11/ 1999 Arimilli et al. (US ) 6 ,043 , 230 A 3 / 2000 Arimilli et al. 6 ,620 , 841 B1 9 / 2003 Fujishita et al . (72 ) Inventors : Ernest A . Carra , Foster City , CA ( US ) ; 6 ,642 , 245 B1 11/ 2003 Liotta et al. 6 , 703 , 396 B1 3 / 2004 Liotta et al . Irene Chen , San Mateo , CA (US ) ; 7 , 176 , 220 B2 2 /2007 Satoh et al. Vahid Zia , Palo Alto , CA (US ) 7 ,419 , 969 B2 9 / 2008 Naidu et al. 7 , 550 , 463 B2 6 / 2009 Yoshida (73 ) Assignee : Gilead Sciences , Inc. , Foster City , CA 7 ,635 , 704 B2 12 /2009 Satoh et al. 7 , 858 , 788 B2 12 / 2010 Yoshida et al . (US ) 8 , 129 , 385 B2 3 / 2012 Johns et al . 8 , 148 , 374 B2 4 / 2012 Desai et al. ( * ) Notice : Subject to any disclaimer , the term of this 8 , 188 , 271 B2 5 / 2012 Yoshida et al .
    [Show full text]
  • Qualitative Study to Explore the Knowledge and Attitude of Pregnant Women Regarding HIV/AIDS Testing in Kotayk Region and in Yerevan, Armenia
    Qualitative study to explore the knowledge and attitude of pregnant women regarding HIV/AIDS testing in Kotayk region and in Yerevan, Armenia Utilizing Professional Publication Framework Henrik Khachatryan, MD, MPH candidate, American University of Armenia Primary Adviser: M. Thompson, MS, DrPH Secondary Adviser: K. White, RN, PhD, CNAA October 2005 Table of Contents INTRODUCTION ...........................................................................................................................................................1 Background Information and Literature review....................................................................................................1 Rationale for the Research and Research Questions.............................................................................................4 METHODS AND MATERIALS........................................................................................................................................5 Study design...........................................................................................................................................................5 Study population ....................................................................................................................................................5 Sampling and Study Setting...................................................................................................................................6 Data collection Instrument.....................................................................................................................................6
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project
    University of Rhode Island DigitalCommons@URI Infectious Diseases in Corrections Report (IDCR) 2003 HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6 HIV & Hepatitis Education Prison Project Follow this and additional works at: http://digitalcommons.uri.edu/idcr Recommended Citation HIV & Hepatitis Education Prison Project, "HEPP Report: Infectious Diseases in Corrections, Vol. 6 No. 6" (2003). Infectious Diseases in Corrections Report (IDCR). Paper 46. http://digitalcommons.uri.edu/idcr/46 This Article is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Infectious Diseases in Corrections Report (IDCR) by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. HIV & HEPATITIS EDUCATION PRISON HEPJune 2003 Vol. 6, Issue 6 P REPORT PROJECT Infectious Diseases in Corrections SPONSOREDBYTHEBROWNMEDICALSCHOOLOFFICEOFCONTINUINGMEDICALEDUCATION. ABOUT HEPP Long-Term Toxicities Associated with HIV and HEPP Report, a forum for Antiretroviral Therapy correctional problem solving, targets correctional physicians, nurses, By Peter J. Piliero, M.D.*, Associate Professor of Medicine, Albany Medical College administrators, outreach workers, and Soon after the introduction of the first antiretroviraldine (3TC) have also been associated with pan- case managers. Published monthly (ARV) agent, zidovudine (AZT), drug-related toxi-creatitis. There may be an added potential for pan- and distributed by email and fax, cities became recognized and well-characterized.creatitis when using combinations of these nucle- HEPP Report provides up-to-the Things have since become more complicated;oside reverse transcriptase inhibitors (NRTIs). moment information HIV/AIDS, there are now 17 ARV agents in four distinct class-Importantly, the concomitant use of alcohol hepatitis, and other infectious es.
    [Show full text]
  • Partners with Mixed HIV Status
    Partners With Mixed HIV Status SERODISCORDANT RELATIONSHIPS Relationships in which one or more people has HIV and one or more people do not have HIV are sometimes called serodiscordant or mixed serostatus. The term serodiscordant is made up of two roots: 1. Sero—meaning blood 2. Discordant—meaning different or non-matching HIV isn’t the first topic that comes up when most people start dating. You may not know the HIV status of your partner(s). You might not even have been tested yourself. It can be very difficult to talk about HIV status. WHAT ARE THE SPECIAL ISSUES FOR SERODISCORDANT RELATIONSHIPS? People in mixed HIV status relationships face all the same things as other people in relationship. But there are some extra issues: The partner(s) with HIV might focus on not infecting their partner(s). The partner(s) who do not have HIV may concentrate on taking care of the person/people with HIV. This can cause a serious lack of balance in the relationship. HIV can cause changes in the body. Antiretroviral medications (ARVs) may have unpleasant side effects. This might give the partner(s) with HIV negative feelings about their body and their health. It may be difficult to feel attractive and have a normal romantic relationship. Fear of transmitting HIV can cause an excess of caution. This might even stop all sexual activity. Review the following fact sheets for more information: Stopping the Spread of HIV Safer Sex Guidelines Condoms Ways HIV is Transmitted Try to have open discussions about your desires, your fears, and your limits.
    [Show full text]
  • WO 2013/164559 Al 7 November 2013 (07.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/164559 Al 7 November 2013 (07.11.2013) P O P C T (51) International Patent Classification: (74) Agent: TURNER, Craig; A.A. Thornton & Co, 235 High A61K 9/16 (2006.01) A61K 31/427 (2006.01) Holborn, London WC1V 7LE (GB). A61K 9/20 (2006.01) A61K 31/513 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 13/000 193 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) Date: International Filing DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 3 May 20 13 (03.05.2013) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (30) Priority Data: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 1380/MUM/2012 3 May 2012 (03.05.2012) IN TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 2590/MUM/2012 6 September 2012 (06.09.2012) IN ZM, ZW.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Abstract Book Towards an HIV Cure Symposium, 2013 Towards an HIV Cure Symposium 2013 Abstract Book 2
    Abstract Book Towards an HIV Cure Symposium, 2013 Towards an HIV Cure Symposium 2013 Abstract Book 2 Contents Oral Abstract Session 1 4 OA1-1 4 OA1-2 5 OA1-3 6 OA1-4 LB 7 OA1-5 LB 8 Oral Abstract Session 2 9 OA2-1 9 OA2-2 10 OA2-3 11 OA2-4 12 OA2-5 LB 13 OA2-6 LB 14 OA2-7 LB 15 Oral Abstract Session 3 16 OA3-1 16 OA3-2 17 OA3-3 18 OA3-4 LB 19 Oral Abstract Session 4 20 OA4-1 20 OA4-2 22 OA4-3 LB 24 OA4-4 LB 25 Poster Exhibition 26 A5 – Entry (attachment, receptors and co-receptors, penetration and tropism) 26 A8 – Regulation of viral gene expression and replication 27 A9 – Cellular factors necessary for HIV replication 28 A10 – Cellular and tissue reservoirs 31 A11 – Mechanisms of HIV persistence 36 A13 – Strategies to target and eradicate reservoirs 37 A14 – Mucosal transmission 43 A19 – Intrinsic cellular defenses and restriction factors 44 A20 – IFN-I (viral inhibition, immunomodulatory functions) 46 Back to Content page Towards an HIV Cure Symposium 2013 Abstract Book 3 A21 – NK cells and dendritic cells 47 A22 – Monocytes and macrophages 49 A24 – Antibody diversity and function 51 A27 – Cellular immunity 53 A28 – Mucosal immunity 56 A29 – Viral determinants of pathogenesis 57 A30 – Acute and early HIV/SIV infection 58 A41 – Elite controllers 59 A44 – Highly exposed seronegative individuals (HESN) 61 A45 – Correlates of protection 62 A46 – HIV drug development 63 A47 – Mechanisms of anti-retroviral drug resistance 65 A49 – Nucleic acid based HIV and SIV therapy development 67 A50 – Design of approaches targeting inflammation/immune
    [Show full text]
  • Sexually Transmitted Diseases Treatment Guidelines, 2015
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory
    [Show full text]
  • Models for Predicting Effective HIV Chemoprevention in Women
    NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 April 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: J Acquir Immune Defic Syndr. 2015 April 1; 68(4): 369–376. doi:10.1097/QAI.0000000000000472. Models for Predicting Effective HIV Chemoprevention in Women Melanie R. Nicol, PharmD, PhD1,*, Cindi W. Emerson, B.S., B.A.1,2, Heather M.A. Prince, MPA2,3, Julie A.E. Nelson, PhD2,3, Yuri Fedoriw, MD3, Craig Sykes, M.S.1,2, Elizabeth J Geller, MD3, Kristine B. Patterson, MD3, Myron S Cohen, MD2,3, and Angela D.M. Kashuba, BScPhm, PharmD1,2,3 1Eshelman School of Pharmacy, University of North Carolina at Chapel Hill 2Center for AIDS Research, University of North Carolina at Chapel Hill 3School of Medicine, University of North Carolina at Chapel Hill Abstract Objective—Model systems which rapidly identify tissue drug concentrations protective of HIV infection could streamline the development of chemoprevention strategies. Tissue models are promising, but limited concentration targets exist, and no systematic comparison to cell models or clinical studies has been performed. Design—We explored efficacy of maraviroc (MVC) and tenofovir (TFV) for HIV prevention by comparing Emax models from TZM-bl cells to vaginal tissue explants, and evaluated their predictive capabilities with a dose-challenge clinical study. Methods—HIV-1JR-CSF was utilized for viral challenge. Drug efficacy was assessed using a luciferase reporter assay in TZM-bl cells and real-time PCR to quantify spliced RNA in a tissue explant model.
    [Show full text]